Preclinical Oncology CRO - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510242899

Publication Date:

October 28, 2024

Pages:

107

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Preclinical research refers to before testing a drug in people, researchers must find out whether it has the potential to cause serious harm, also called toxicity. A Preclinical CRO, or preclinical contract research organization, provides the experience, knowledge, and skill required to take a pharmaceutical product or medical device from the drawing board to distribution. This journey entails a plethora of activities that involve scientists, medical personnel, administrators, governmental and industry liaisons, marketing experts, and a host of other technical and creative individuals. Rarely is this unique combination of credentials and craft already present within a sponsoring organization. The CRO industry emerged to fill this much-needed role, to provide the expertise required to bring a pharmaceutical product or medical device into the marketplace as quickly and smoothly as possible.
The global market for Preclinical Oncology CRO was estimated to be worth US$ 380.3 million in 2023 and is forecast to a readjusted size of US$ 876.2 million by 2030 with a CAGR of 12.4% during the forecast period 2024-2030
The industry's leading producers are Crown Bioscience, Charles River and ICON, with revenues of 18.32 percent, 13.86 percent and 9.13 percent in 2019.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Preclinical Oncology CRO, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Preclinical Oncology CRO by region & country, by Type, and by Application.
The Preclinical Oncology CRO market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Preclinical Oncology CRO.
麻豆原创 Segmentation
By Company
Crown Bioscience
Charles River Laboratory
ICON Plc.
Eurofins Scientific
Taconic Biosciences
Covance
EVOTEC
The Jackson Laboratory
Wuxi AppTec.
MI Bioresearch, Inc.
Champion Oncology, Inc.
Xentech
Segment by Type:
Blood Cancer
Solid Tumors
Other
Segment by Application
In Vitro
In Vivo
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Preclinical Oncology CRO manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Preclinical Oncology CRO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Preclinical Oncology CRO in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Preclinical Oncology CRO Product Introduction
1.2 Global Preclinical Oncology CRO 麻豆原创 Size Forecast
1.3 Preclinical Oncology CRO 麻豆原创 Trends & Drivers
1.3.1 Preclinical Oncology CRO Industry Trends
1.3.2 Preclinical Oncology CRO 麻豆原创 Drivers & Opportunity
1.3.3 Preclinical Oncology CRO 麻豆原创 Challenges
1.3.4 Preclinical Oncology CRO 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Preclinical Oncology CRO Players Revenue Ranking (2023)
2.2 Global Preclinical Oncology CRO Revenue by Company (2019-2024)
2.3 Key Companies Preclinical Oncology CRO Manufacturing Base Distribution and Headquarters
2.4 Key Companies Preclinical Oncology CRO Product Offered
2.5 Key Companies Time to Begin Mass Production of Preclinical Oncology CRO
2.6 Preclinical Oncology CRO 麻豆原创 Competitive Analysis
2.6.1 Preclinical Oncology CRO 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Preclinical Oncology CRO Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Preclinical Oncology CRO as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Blood Cancer
3.1.2 Solid Tumors
3.1.3 Other
3.2 Global Preclinical Oncology CRO Sales Value by Type
3.2.1 Global Preclinical Oncology CRO Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Preclinical Oncology CRO Sales Value, by Type (2019-2030)
3.2.3 Global Preclinical Oncology CRO Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 In Vitro
4.1.2 In Vivo
4.2 Global Preclinical Oncology CRO Sales Value by Application
4.2.1 Global Preclinical Oncology CRO Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Preclinical Oncology CRO Sales Value, by Application (2019-2030)
4.2.3 Global Preclinical Oncology CRO Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Preclinical Oncology CRO Sales Value by Region
5.1.1 Global Preclinical Oncology CRO Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Preclinical Oncology CRO Sales Value by Region (2019-2024)
5.1.3 Global Preclinical Oncology CRO Sales Value by Region (2025-2030)
5.1.4 Global Preclinical Oncology CRO Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Preclinical Oncology CRO Sales Value, 2019-2030
5.2.2 North America Preclinical Oncology CRO Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Preclinical Oncology CRO Sales Value, 2019-2030
5.3.2 Europe Preclinical Oncology CRO Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Preclinical Oncology CRO Sales Value, 2019-2030
5.4.2 Asia Pacific Preclinical Oncology CRO Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Preclinical Oncology CRO Sales Value, 2019-2030
5.5.2 South America Preclinical Oncology CRO Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Preclinical Oncology CRO Sales Value, 2019-2030
5.6.2 Middle East & Africa Preclinical Oncology CRO Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Preclinical Oncology CRO Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Preclinical Oncology CRO Sales Value
6.3 United States
6.3.1 United States Preclinical Oncology CRO Sales Value, 2019-2030
6.3.2 United States Preclinical Oncology CRO Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Preclinical Oncology CRO Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Preclinical Oncology CRO Sales Value, 2019-2030
6.4.2 Europe Preclinical Oncology CRO Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Preclinical Oncology CRO Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Preclinical Oncology CRO Sales Value, 2019-2030
6.5.2 China Preclinical Oncology CRO Sales Value by Type (%), 2023 VS 2030
6.5.3 China Preclinical Oncology CRO Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Preclinical Oncology CRO Sales Value, 2019-2030
6.6.2 Japan Preclinical Oncology CRO Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Preclinical Oncology CRO Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Preclinical Oncology CRO Sales Value, 2019-2030
6.7.2 South Korea Preclinical Oncology CRO Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Preclinical Oncology CRO Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Preclinical Oncology CRO Sales Value, 2019-2030
6.8.2 Southeast Asia Preclinical Oncology CRO Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Preclinical Oncology CRO Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Preclinical Oncology CRO Sales Value, 2019-2030
6.9.2 India Preclinical Oncology CRO Sales Value by Type (%), 2023 VS 2030
6.9.3 India Preclinical Oncology CRO Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Crown Bioscience
7.1.1 Crown Bioscience Profile
7.1.2 Crown Bioscience Main Business
7.1.3 Crown Bioscience Preclinical Oncology CRO Products, Services and Solutions
7.1.4 Crown Bioscience Preclinical Oncology CRO Revenue (US$ Million) & (2019-2024)
7.1.5 Crown Bioscience Recent Developments
7.2 Charles River Laboratory
7.2.1 Charles River Laboratory Profile
7.2.2 Charles River Laboratory Main Business
7.2.3 Charles River Laboratory Preclinical Oncology CRO Products, Services and Solutions
7.2.4 Charles River Laboratory Preclinical Oncology CRO Revenue (US$ Million) & (2019-2024)
7.2.5 Charles River Laboratory Recent Developments
7.3 ICON Plc.
7.3.1 ICON Plc. Profile
7.3.2 ICON Plc. Main Business
7.3.3 ICON Plc. Preclinical Oncology CRO Products, Services and Solutions
7.3.4 ICON Plc. Preclinical Oncology CRO Revenue (US$ Million) & (2019-2024)
7.3.5 Eurofins Scientific Recent Developments
7.4 Eurofins Scientific
7.4.1 Eurofins Scientific Profile
7.4.2 Eurofins Scientific Main Business
7.4.3 Eurofins Scientific Preclinical Oncology CRO Products, Services and Solutions
7.4.4 Eurofins Scientific Preclinical Oncology CRO Revenue (US$ Million) & (2019-2024)
7.4.5 Eurofins Scientific Recent Developments
7.5 Taconic Biosciences
7.5.1 Taconic Biosciences Profile
7.5.2 Taconic Biosciences Main Business
7.5.3 Taconic Biosciences Preclinical Oncology CRO Products, Services and Solutions
7.5.4 Taconic Biosciences Preclinical Oncology CRO Revenue (US$ Million) & (2019-2024)
7.5.5 Taconic Biosciences Recent Developments
7.6 Covance
7.6.1 Covance Profile
7.6.2 Covance Main Business
7.6.3 Covance Preclinical Oncology CRO Products, Services and Solutions
7.6.4 Covance Preclinical Oncology CRO Revenue (US$ Million) & (2019-2024)
7.6.5 Covance Recent Developments
7.7 EVOTEC
7.7.1 EVOTEC Profile
7.7.2 EVOTEC Main Business
7.7.3 EVOTEC Preclinical Oncology CRO Products, Services and Solutions
7.7.4 EVOTEC Preclinical Oncology CRO Revenue (US$ Million) & (2019-2024)
7.7.5 EVOTEC Recent Developments
7.8 The Jackson Laboratory
7.8.1 The Jackson Laboratory Profile
7.8.2 The Jackson Laboratory Main Business
7.8.3 The Jackson Laboratory Preclinical Oncology CRO Products, Services and Solutions
7.8.4 The Jackson Laboratory Preclinical Oncology CRO Revenue (US$ Million) & (2019-2024)
7.8.5 The Jackson Laboratory Recent Developments
7.9 Wuxi AppTec.
7.9.1 Wuxi AppTec. Profile
7.9.2 Wuxi AppTec. Main Business
7.9.3 Wuxi AppTec. Preclinical Oncology CRO Products, Services and Solutions
7.9.4 Wuxi AppTec. Preclinical Oncology CRO Revenue (US$ Million) & (2019-2024)
7.9.5 Wuxi AppTec. Recent Developments
7.10 MI Bioresearch, Inc.
7.10.1 MI Bioresearch, Inc. Profile
7.10.2 MI Bioresearch, Inc. Main Business
7.10.3 MI Bioresearch, Inc. Preclinical Oncology CRO Products, Services and Solutions
7.10.4 MI Bioresearch, Inc. Preclinical Oncology CRO Revenue (US$ Million) & (2019-2024)
7.10.5 MI Bioresearch, Inc. Recent Developments
7.11 Champion Oncology, Inc.
7.11.1 Champion Oncology, Inc. Profile
7.11.2 Champion Oncology, Inc. Main Business
7.11.3 Champion Oncology, Inc. Preclinical Oncology CRO Products, Services and Solutions
7.11.4 Champion Oncology, Inc. Preclinical Oncology CRO Revenue (US$ Million) & (2019-2024)
7.11.5 Champion Oncology, Inc. Recent Developments
7.12 Xentech
7.12.1 Xentech Profile
7.12.2 Xentech Main Business
7.12.3 Xentech Preclinical Oncology CRO Products, Services and Solutions
7.12.4 Xentech Preclinical Oncology CRO Revenue (US$ Million) & (2019-2024)
7.12.5 Xentech Recent Developments
8 Industry Chain Analysis
8.1 Preclinical Oncology CRO Industrial Chain
8.2 Preclinical Oncology CRO Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Preclinical Oncology CRO Sales Model
8.5.2 Sales Channel
8.5.3 Preclinical Oncology CRO Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Crown Bioscience
Charles River Laboratory
ICON Plc.
Eurofins Scientific
Taconic Biosciences
Covance
EVOTEC
The Jackson Laboratory
Wuxi AppTec.
MI Bioresearch, Inc.
Champion Oncology, Inc.
Xentech

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.